{"links":{"html":"https://www.erudio.com/reports/rosetta-lung-107-nct06841055","json":"https://www.erudio.com/reports/rosetta-lung-107-nct06841055.json","markdown":"https://www.erudio.com/reports/rosetta-lung-107-nct06841055.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rosetta-lung-107-06841055"}},"request":"https://www.erudio.com/contact?report=rosetta-lung-107-06841055"},"offer":{"cited_commentary_sources":5,"verified_hcp_statements":16,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":2,"optional":true,"price_per_verified_person_usd":15,"price_usd":30,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rosetta-lung-107-nct06841055"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rosetta-lung-107-06841055","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rosetta-lung-107-nct06841055","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T07:48:00.897475Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":1,"title":"Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":4,"title":"Primary endpoint: Part 1 and Part 2 - Objective response rate"},{"claim_count":7,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":3,"title":"PD-L1 and histology: breadth of activity versus differential benefit"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Potential immune re-engagement after chemoimmunotherapy"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Alternative immune–angiogenic combinations"}],"counts":{"cited_sources":5,"claims_by_expression_type":{"comparison":3,"interpretation":3,"opinion":3,"question":1,"restatement":6},"claims_by_kind":{"source_observation":16},"clinician_statements":2,"evidence_units":5,"findings":4,"organisational_accounts":2,"people_cited":2,"people_identity_verified":2,"people_total":2,"screened_sources":14,"verified_claims":16},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"An encouraging signal leaves the added-benefit question unanswered"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Reassurance about safety coexists with high-grade toxicity and differing bleeding summaries"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Activity across subgroups supports further study, not a selection rule or proven mechanism"},{"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":false,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Strategy-level enthusiasm does not rank alternative docetaxel combinations"}],"medical_affairs_question":"Would a randomized comparison show that adding pumitamig improves outcomes over contemporary second-line treatment?","sections":{"analysis":[{"id":"section-1","level":3,"title":"An encouraging signal leaves the added-benefit question unanswered"},{"id":"section-2","level":3,"title":"Safety reassurance includes squamous disease, but does not mean negligible toxicity"},{"id":"section-3","level":3,"title":"Subgroup breadth encourages investigation; immune re-engagement remains a hypothesis"},{"id":"section-4","level":3,"title":"Enthusiasm for immune–angiogenic strategies is explicitly noncomparative"},{"id":"section-5","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":2}],"id":"T1","label":"Primary endpoint: Part 1 - Occurrence of dose limiting toxicities (DLTs)"},{"findings":[{"id":"F2","shared_claims":5}],"id":"T2","label":"Primary endpoint: Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T3","label":"Primary endpoint: Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T4","label":"Primary endpoint: Part 1 and Part 2 - Objective response rate"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T5","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":5}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T07:48:00.897475Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T08:16:24Z","record_hash":"bf2916f4d60ce6fedeb4a9c757dcc6bdf3c674ef6c7ded6d35922985a91abec8","release_hash":"a4bda293047aa55a658c48ddb3008069b9a3e3888436949881cea4aa2086570b","report_id":"erudio-nct06841055","run_id":"2985a5e3-ddc5-45b5-940d-1e2e99b80a13","schema_version":"5.0","slug":"rosetta-lung-107-06841055","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ROSETTA Lung-107 examines whether pumitamig with chemotherapy can improve outcomes in NSCLC, with discussion focused on docetaxel after chemoimmunotherapy. In the sources reviewed for this edition, favorable clinical reactions coexist with an unresolved added-benefit question. A medical oncologist expresses safety reassurance and relayed investigator remarks welcome activity; X-thread discussions scrutinize comparative benefit. How subgroup findings should guide treatment selection, and how alternative docetaxel combinations compare, remain open.","meta_description":"14 sources screened · 16 verified statements (2 from clinicians verified by NPI or staff page) from 5 sources · 4 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-28T08:16:24Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-28T09:50:00Z","summary":"The trial is named ROSETTA Lung-107, as its sources and the report name it (was BNT327-07)"},{"affected_ids":[],"date":"2026-10-28T09:55:00Z","summary":"Corrected to match the delivered report: the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":14},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","8 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not a representative survey of HCPs. Presentation summaries, relayed statements and account commentary should not be counted as independent clinician endorsements.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No results publication for NCT06841055 was found, no protocol was listed on ClinicalTrials.gov, and no exact pumitamig regulatory label was identified. The report describes commentary, not a complete assessment of the trial or prescribing information.","The safety summaries differ on bleeding severity, reporting grade 1 versus grades 1 or 2; the available statements do not explain the difference.","Historical and cross-study comparisons, descriptive subgroup results and a relayed mechanistic hypothesis do not establish comparative efficacy, comparative safety or a treatment-selection rule."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":5},"count":5,"evidence_window":{"end":"2026-10-25","start":"2026-10-25"},"retrieval_snapshot":"2026-10-28T07:31:48.474952Z","timeline":[{"count":5,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06841055:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06841055:context","quote_policy":"short_quote_link_out"},{"id":"openfda:2992d633-08fa-44f3-b14d-41700f24686b:20260415","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-axbq3ziqaqvmkd22kzwpiil4-3mypulttdxi2o","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103831965845909942:9e6ed0b2-fe5b-4949-99aa-9d1d80596eb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112138773001547984:074db8d8-9cb4-4285-87ca-16118ea7fae4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113978819258277901:d1a798dd-495f-4a7d-92a8-542795b8d9a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114209098946289675:9e9b830c-ba36-43b2-9d1b-1eb6c80c64e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114259232568603083:a3f6df46-5631-48ac-8c0c-68a5a2a3488b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114260397104713970:35ee99c2-4b6a-4446-84cf-98ce553e1ced","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114262855029555505:1843fe2f-5aee-4b49-b150-57b6ce41f109","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114262916572561437:1260e415-80d4-47e5-ad35-019b0760230b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114263076639756485:d6c44cb5-24cf-442f-82dd-545ede9139e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114269880853876758:812af20d-7fde-40f8-9008-b8723fcc0e31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114312245068881995:54299fbc-690a-4333-bee2-027364149794","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114371021319131428:bbc7af86-ec6f-4561-a6a1-0f33752f95f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114430146740453541:ab2689cd-e18d-4ac4-a3ef-1488e4200035","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":13,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-10-25","start":"2026-09-26"},"retrieval_snapshot":"2026-10-28T07:31:48.474952Z","timeline":[{"count":1,"week":"2026-W39"},{"count":13,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pumitamig","status":"unmapped"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ROSETTA Lung-107","aliases":["ROSETTA Lung-107","Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)"],"brief_title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","collaborators":["BioNTech (Shanghai) Pharmaceuticals Co., Ltd."],"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":60,"type":"ESTIMATED"},"interventions":[{"name":"Pumitamig","synonyms":["BNT327","PM8002","BMS-986545"],"type":"DRUG"},{"name":"Docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06841055","official_title":"A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC)","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2028-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"During the DLT evaluation period by dose level","measure":"Part 1 - Occurrence of dose limiting toxicities (DLTs)","timeFrame":"Up to 21 days after first dose of investigational medicinal product (IMP)"},{"description":"Graded according to the (United States) National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)","measure":"Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest","timeFrame":"From initiation of the first dose of IMP to the 90-day Follow-Up visit"},{"measure":"Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events","timeFrame":"From initiation of the first dose of IMP until the 90-day Safety Follow-up visit"},{"description":"Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) based on investigator's review) is observed as best overall response.","measure":"Part 1 and Part 2 - Objective response rate","timeFrame":"Up to approximately 2 years"}],"registry_last_updated":"2026-04-24","registry_url":"https://clinicaltrials.gov/study/NCT06841055","short_name":"ROSETTA Lung-107","short_name_basis":"canonical_name","sponsor":"BioNTech SE","start_date":{"date":"2025-03-03","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase2","study_ids":[{"id":"BNT327-07","type":"sponsor_study_id"},{"id":"2024-518279-80-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}